Bioheart Inc., a Cardiovascular Disease Management Organization, Provides Patients with Products to Prevent Heart Attacks as well as Assisting Those Who Have Suffered a Heart Attack to Return to a Full Quality of Life

FT. LAUDERDALE, Fla., Sept. 15 /PRNewswire/ -- Bioheart Inc., translating the human genome for patient care, is presenting at the EMT East Trade Show. -- Presenter -- Dr. Howard B. Haimes - Director of Business Development Howard B. Haimes, Ph.D., joined Bioheart Inc. as a consultant in December of 1999 and full-time as Director of Business Development -- June 2000. His scientific achievements have resulted in several issued patents and an approved IND application on a new chemical entity. Dr. Haimes received his doctoral training at the Albert Einstein College of Medicine and did postdoctoral studies at Vanderbilt University with Nobel Laureate Dr. Stanley Cohen. He served as a visiting scientist in the Department of Biology at M.I.T. and became a founding member of Organogenesis, Inc (ORG). He was subsequently Directors of Animal Pathology and Biological Sciences at OsteoArthritis Sciences, Inc. Dr. Haimes will present the core technologies of Bioheart Inc.: * Bioheart Inc. Microimplant -- Myogenesis Program consists of the implantation of autologous, immature myoblasts into damaged or diseased heart muscle. Preclinical studies in a variety of animal species have documented increases in the function of the heart subsequent to cell transplantation. Summaries of the key, pivotal animal studies as well as the company's device delivery technology will be presented. The thoracoscopic, epicardial and percutaneous endovascular devices will be described. The use of autologous cell transplantation will represent one of the first true therapies for treating the cause of disease states such as congestive heart failure. Bioheart's autologous cell source consists of myoblasts (skeletal muscle cells), easily attainable from a 2 gram muscle biopsy have proven as an effective cell source for heart muscle regeneration because they are committed to become muscle, are resistant to ischemia, do not over proliferate and are able to withstand cardiac workload. The work of Dr. Doris Taylor, Vice President of Research and Assistant Professor at Duke University, recognized, as the leading scientist in the field of heart muscle tissue regeneration will be presented along with that of other strategic collaborators. Bioheart's method for regenerating heart muscle tissue is being replicated around the world. Future product development efforts will be devoted to the implantation of a biological pacemaker. * Bioheart Inc. Genotyping -- "Translating the Human Genome for Patient Care" Bioheart is positioning itself to become the primary resource to cardiologists for genetic tests that identify cardiovascular risk factors for which there is a therapeutic solution. Bioheart is currently launching its proprietary PLA2 test for the identification of thrombosis susceptibility and predisposition to early heart attack. This test directs the customization of anticoagulant therapy based on one's genetic background. Bioheart has introduced four additional panels of genetic cardiovascular risk factors. Dr. Haimes will portray the value of the strategic intellectual property portfolio. When taken as a whole we believe we have assembled the strongest portfolio of intellectual property in the field of myocardial regeneration and device delivery technology. Bioheart Inc. Milestones Event Anticipated Date Human cases Accomplished Initiate European clinical trial October 2000 Initiate US clinical trial January 2000 Foreign sales First quarter 2001 FDA Approval Fourth quarter 2003 MANAGEMENT TEAM Mr. Leonhardt, the founder of World Medical Manufacturing, that was acquired by AVE/Medtronic for approximately $70 million. Mr. Lashinski was the co-founder of AVE, a leading coronary stent and balloon catheter manufacturer that was sold to Medtronic for approximately $4 billion, will lead the development of our delivery systems as Chief Consultant of Product Development. John L. Babitt, Jr., CPA, Chief Financial Officer, joined the Company from Ernst & Young, LLP. Bioheart has also established an impressive array of strategic partners including, Dr. Taylor, Duke University, Dr. Chiu, McGill University, Dr. Race Kao, East Tennessee State, Dr. Phillippe Menasche, Dr. Charles Murray, a leading cardiovascular pathologist, IntroGene, The Cleveland Clinic Foundation, Columbia University and Lenox Hill. FINANCIAL FORECAST Bioheart Inc. has recently closed an $8 million private equity financing and expects to conclude a $20 - $25 Million Series B round of financing with a strategic corporate partner in Q4 to support clinical trials and operations into mid-2002.